Content of the article
An extensive study launched by the Montreal Heart Institute last March concluded that the anti-inflammatory drug colchicine may reduce some of the complications associated with COVID-19.
In a news release Friday, the institute described its findings as a “major scientific discovery” that could help millions of COVID-19 patients around the world.
Colchicine, an oral tablet that is cheap and easy to make, is already known and used for other diseases. The study looked at its effects on 4,159 patients with COVID-19.
Participating patients had to be over 40 years of age and have at least one risk factor for possible complications. The results showed that the drug helped reduce hospitalizations by a quarter, the need for mechanical ventilation by half and deaths by 44%.
Participating researchers believe that colchicine may be the first oral drug used to treat non-hospitalized patients with COVID-1